These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1643634)

  • 41. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M; Droz JP; Hanauske AR; Verweij J; van Oosterom AT; Groen HJ; Pacciarini MA; Domenigoni L; van Weissenbruch F; Pianezzola E; de Vries EG
    Br J Cancer; 1998; 77(1):139-46. PubMed ID: 9459159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
    Geroni C; Pesenti E; Broggini M; Belvedere G; Tagliabue G; D'Incalci M; Pennella G; Grandi M
    Br J Cancer; 1994 Feb; 69(2):315-9. PubMed ID: 8297727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular models for multiple drug resistance in cancer.
    Clynes M
    In Vitro Cell Dev Biol; 1993 Mar; 29A(3 Pt 1):171-9. PubMed ID: 8096505
    [No Abstract]   [Full Text] [Related]  

  • 44. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.
    Lau DH; Duran GE; Lewis AD; Sikic BI
    Br J Cancer; 1994 Jul; 70(1):79-84. PubMed ID: 8018545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
    Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
    Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
    Lu H; Waxman DJ
    Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes.
    Lewis AD; Lau DH; Durán GE; Wolf CR; Sikic BI
    Cancer Res; 1992 Aug; 52(16):4379-84. PubMed ID: 1643634
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.